Efficacy And Safety Of Mitiglinide Calcium Versus Nateglinide In Newly Diagnose Patients With Type2Diabetes Mellitus

Objective To explore the efficacy and safety of mitiglinide calcium andnateglinide in newly diagnosed patients with type2diabetesmellitus(T2DM).Methods225cases of newly diagnosed patients with T2DM,throughthe principle of a randomized,double-blind and parallel group,divided intomitiglinide calcium group（N=111） and nateglinide group（N=114）.Patients were given respectively mitigliide calcium dispersible tablets andnateglinide tablets in the treatment course of16weeks.To determine theefficacy and safety indicators of before and after treatment fasting bloodglucose(FBG),2-hour postprandial blood glucose(2hPBG),glycosylatedhemoglobin(HbA1c) and fasting insulin(FINS),and to analysis of its clinicalsignificance.Results Before treatment, no significant difference in gender, age, bodymass index (BMI), SBP, DBP, body fat percentage (FAT), FBG,2hPBG,HbA1c, FINS and blood lipid (P>0.05).After treatment,the two groups ofFBG,2hPBG and HbA1c were significantly decreased (P<0.05orP<0.01).Mitiglinide calcium group of FINS and HOMA-IR wassignificantly lower (24.19±25.50vs17.48±16.04mU/L;9.01±1.90vs6.25±1.27, P <0.05).There was no significant difference between the twogroups before treatment (P>0.05).The changes between the two groupsbefore and after treatment were in no value of statistical significance(P>0.05)., but the compliance rate of HbA1c in Mitiglinide calcium groupwas higher than the nateglinide group. No significant difference between the two groups lipids, liver and kidney function and other indicators of safetyand adverse reactions.Conclusions As a new hypoglycemic agent, mitiglinide calcium has adefinite efficacy and highly safety.